Login

Tipo di accesso

Password dimenticata? Clicca qui

LOGIN
Annulla
Forgot error
DMP_ForgotOK Close

REGISTRATI

Se sei un Medico o un Giornalista e non hai ancora un account Dompé, clicca qui per accedere al modulo di registrazione.

REGISTRATI
 

News

Dompé receives Industry Innovation Award from the National Organization for Rare Disorders for the Development of Oxervate eye drops (cenegermin-bkbj), for neurotrophic keratitis

  • Oxervate is the first treatment indicated for neurotrophic keratitis, the first-ever application of a recombinant human nerve growth factor as drug or treatment, and the first-ever topical biologic medication approved in ophthalmology
  • Oxervate clinical trial results have shown complete corneal healing in up to 72% of patients after 8 weeks of treatment, defined as absence of staining in the lesion area and no persistent staining in the rest of the cornea
  • The Rare Impact Award recognizes Dompé's achievement in innovation to improve the lives of people with a rare, debilitating disease

MILAN and SAN BRUNO, Calif., March 12, 2019 /PRNewswire/ - Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé), announced today that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefitting rare disease patients and caregivers. Oxervate (cenegermin-bkbj) ophthalmic solution 0.002% was approved by the U.S. Food and Drug Administration (FDA) in August 2018 as the first therapy specifically indicated to treat neurotrophic keratitis (NK), a rare and progressive eye disease that can impact the cornea, leading to scarring and reduced visual acuity.

"At NORD, we remain committed to increasing attention on rare diseases that impact day-to-day living for those who suffer from them," said Peter L. Saltonstall, President and CEO of NORD. "We are proud to honor Dompé with an Industry Innovation Award and to thank them for the work they are doing on behalf of the rare disease community."

Dompé supports the rare disease community through continued research and development activity in rare diseases, support of NORD's RareCare® program, and membership on NORD's corporate council.

"Dompé is extremely proud of the development program that resulted in the FDA approval of Oxervate.  In neurotrophic keratitis, we saw a devastating disease without any approved pharmacologic treatments targeting the root pathogenesis. We are honored to be able to offer this breakthrough therapy to patients who have been waiting for an effective and non-invasive option," said Sergio Dompé, Chairman of Dompé. "We would like to thank NORD for the Industry Innovation Award. We are inspired by our patients and their caregivers, and we remain committed to innovation for the benefit of patients facing even the rarest of conditions."

The Rare Impact Awards will take place on Saturday, June 22 at Space Center Houston, the Official Visitor Center of NASA Johnson Space Center and a Smithsonian Affiliate.

About NORD

The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases. NORD is committed to the identification, treatment, and cure of the more than 7,000 rare diseases, of which approximately 90% are still without an FDA-approved treatment or therapy. Rare diseases affect 25-30 million Americans. More than half of those affected are children.

NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983. For more than 35 years, NORD has led the way in voicing the needs of the rare disease community, driving supportive policies and education, advancing medical research, and providing patient and family services for those who need them most.  NORD represents more than 280 disease-specific member organizations and their communities and collaborates with many other organizations in specific causes of importance to the rare disease patient community.

Oxervate: Safety and Efficacy Data

The efficacy and safety of Oxervate in Neurotrophic Keratitis (NK) was established in two independent, double-masked, randomized, multi-center, controlled clinical trials. This program represents the largest combined population of patients with NK ever examined in randomized controlled trials. Both trials studied Oxervate (20 mcg/mL) as compared to vehicle among patients with moderate (Stage 2) or severe (Stage 3) NK. Study NGF0212 (REPARO), which was conducted in Europe, randomized 52 patients to each group. REPARO also tested 10mcg/ml as compared to vehicle. After eight weeks, 72.0 percent of patients in the 20mcg/mL group were completely healed vs 33.3 percent in the vehicle group after 8 weeks. Study NGF0214, conducted in the U.S., randomized 24 patients to each group, and 65.2 percent in the 20mcg/mL group were completely healed vs 16.7 percent in the vehicle group after 8 weeks. Both studies included a follow-up period, in REPARO it was 48 weeks, and in Study NGF0214 it was 24 weeks. In REPARO, the study with the longer follow-up, approximately 80 percent of patients who healed during the eight-week treatment period remained healed after one year.

Oxervate was well tolerated in clinical trials, adverse effects were mostly local, mild, and transient. Eye pain was the most frequent adverse reaction reported in 16% of patients. Investigators reported that restoring corneal innervation and sensitivity (which, in turn, will promote corneal healing) can be associated with increased ocular surface symptoms. Other adverse events reported in 1-10% of patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation and tearing. Patients should remove contact lenses before applying Oxervate and wait 15 minutes after instillation of the dose before reinsertion. Findings from the REPARO trial program are published in the September 2018 issue of Ophthalmology, the journal of the American Academy of Ophthalmology. Topline data from the confirmatory NGF0214 study were presented at the 2017 Congress of the European Society of Ophthalmology, and trial results are in preparation for publication.

About Neurotrophic Keratitis

Neurotrophic keratitis, also known as neurotrophic keratopathy, is a rare disease that can be caused by damage to any level of the fifth cranial (trigeminal) nerve. Causes of impaired corneal sensation include herpetic or other infections, ocular or neurologic surgeries, physical injury to the ocular surface, and some systemic conditions that impair sensation. Diagnosis, prognosis, and treatment are based on disease severity, which is classified into three stages. Stage 1 (mild) exhibits ocular surface irregularity and blurred vision, stage 2 (moderate) exhibits a recurrent persistent epithelial defect (PED), and stage 3 (severe) exhibits corneal ulceration involving subepithelial (stromal) tissue, which may progress to corneal melting and perforation. Neurotrophic keratitis affects fewer than 65,000 individuals in the U.S. based on epidemiological data on conditions associated with NK. Patients with advanced stages of neurotropic keratitis are typically treated by cornea specialists.

The cornea is the most densely innervated tissue in humans, with approximately 7,000 nerve endings per square millimeter. These nerves are unique in providing support to the cornea, which is crucial to help maintain transparency in this tissue that is normally devoid of blood vessels. In fact, corneal nerves help maintain ocular surface health by producing soluble factors called neurotrophins and facilitating sensory-dependent blinking and tearing reflexes.

About Oxervate (Cenegermin-bkbj) Ophthalmic Solution

Oxervate is a topical solution 0.002% of cenegermin-bkbj (20 mcg/mL) administered every two hours, six times per day, for eight weeks for the treatment of neurotrophic keratitis. Its active ingredient is cenegermin, a recombinant form of human nerve growth factor. Nerve growth factor (NGF) acts through specific high-affinity and low-affinity nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.

More information about Oxervate can be found in the full prescribing information on the product: www.oxervate.com. Oxervate is now commercially available in the U.S. and can be ordered through Accredo Specialty Pharmacy by calling 1-877-831-8112.

Important Safety Information

The most common adverse reaction in clinical trials that occurred more frequently with Oxervate was eye pain (16% of patients).  Adverse reactions included corneal deposits, foreign body sensations in the eye, ocular hyperemia (enlarged blood vessels in the white of the eyes), swelling (inflammation) of the eye, and increase of tears (1-10% of patients).

Contact lenses should be removed before applying Oxervate because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion.  Lenses may be reinserted 15 minutes after administration.

Oxervate may cause mild to moderate eye discomfort such as eye pain during treatment.  The patient should be advised to contact their doctor if a more serious eye reaction occurs.